PT  - JOURNAL ARTICLE
AU  - Li, Yijia
AU  - Choudhary, Manish C.
AU  - Regan, James
AU  - Boucau, Julie
AU  - Nathan, Anusha
AU  - Speidel, Tessa
AU  - Liew, May Yee
AU  - Edelstein, Gregory E.
AU  - Kawano, Yumeko
AU  - Uddin, Rockib
AU  - Deo, Rinki
AU  - Marino, Caitlin
AU  - Getz, Matthew A.
AU  - Reynold, Zahra
AU  - Barry, Mamadou
AU  - Gilbert, Rebecca F.
AU  - Tien, Dessie
AU  - Sagar, Shruti
AU  - Vyas, Tammy D.
AU  - Flynn, James P.
AU  - Hammond, Sarah P.
AU  - Novack, Lewis A.
AU  - Choi, Bina
AU  - Cernadas, Manuela
AU  - Wallace, Zachary S.
AU  - Sparks, Jeffrey A.
AU  - Vyas, Jatin M.
AU  - Seaman, Michael S.
AU  - Gaiha, Gaurav D.
AU  - Siedner, Mark J.
AU  - Barczak, Amy K.
AU  - Lemieux, Jacob E.
AU  - Li, Jonathan Z.
TI  - SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency
AID  - 10.1101/2023.07.31.23293441
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.31.23293441
4099  - http://medrxiv.org/content/early/2023/08/07/2023.07.31.23293441.short
4100  - http://medrxiv.org/content/early/2023/08/07/2023.07.31.23293441.full
AB  - Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged SARS-CoV-2 infection, but the immune defects that predispose to persistent COVID-19 remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median time to nasal viral RNA and culture clearance in the severe hematologic malignancy/transplant group (S-HT) were 72 and 40 days, respectively, which were significantly longer than clearance rates in the severe autoimmune/B-cell deficient (S-A), non-severe, and non-immunocompromised groups (P<0.001). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and a higher risk of developing antiviral treatment resistance. Both S-HT and S-A participants had diminished SARS-CoV-2-specific humoral, while only the S-HT group had reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19 across immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection.Competing Interest StatementDr. JZ Li was supported by a grant from Merck. The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.Clinical Protocols https://www.positivesstudy.org/ Funding StatementThis work was supported by the National Institutes of Health (U19 AI110818), the Massachusetts Consortium for Pathogen Readiness SARS-CoV-2 Variants Program and the Massachusetts General Hospital Department of Medicine. Drs. JA Sparks and ZS Wallace are supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR080659). Dr. JA Sparks is also supported by the Llura Gund Award funded by the Gordon and Llura Gund Foundation. Dr. GD Gaiha is supported by the NIH (DP2AI154421, R01AI176533 and DP1DA058476), the Bill and Melinda Gates Foundation, Burroughs Wellcome Career Award for Medical Scientists and Howard Goodman Fellowship. Dr. JZ Li was also supported by a grant from Merck. Dr. Y Li was supported by Rustbelt CFAR (Case Western Reserve University/University Hospitals Cleveland Medical Center and University of Pittsburgh, P30 AI036219). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 AI060354). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Mass General Brigham gave ethical approval for this work. All participants have signed informed consent upon entry to the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors